Treatment of severe IgA nephropathy with omega-3 fatty acids: The effect of a "very low dose" regimen

Renal Failure

Volumn 26, Issue 4, 2004, Pages 453-459

  Alexopoulos, Efstathios ^a   Stangou, Maria ^a   Pantzaki, Aphroditi ^a   Kirmizis, Dimitrios ^a   Memmos, Dimitrios ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

Fish oil treatment; IgA nephropathy; Omega 3 fatty acids

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; EDETATE CHROMIUM CR 51; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; CREATININE; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; SEVERITY OF ILLNESS INDEX;

EID: 4444346216     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200026763     Document Type: Article

References (23)

1. D'Amico, G. The commonest glomerulonephritis in the world: IgA nephropathy. Q. J. Med. 1987, 645, 709-727.
2. D'Amico, G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am. J. Kidney Dis. 2000, 36, 227-237.
3. Schmekel, B.; Svalander, C.; Bucht, H.; Westberg, N.G. Mesangial IgA glomerulonephritis in adults and histopathological observations. Acta Med. Scand. 1981, 210, 363-372.
4. Habib, R.; Niaudet, P.; Levey, M. Schönlein-Henoch purpura nephritis and IgA nephropathy. In Renal Pathology with Clinical and Functional Correlations, 2nd Ed.; Tisher, C.C., Brenner, B.M., Eds.; JB Lippincott: Philadelphia, 1994; 472-523.
5. Alexopoulos, E.; Seron, D.; Hartley, R.B.; et al. The role of interstitial infiltrates in IgA nephropathy. A study with monoclonal antibodies. Nephrol. Dial. Transplant. 1989, 4, 187-195.
6. Donadio, J.V., Jr. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin. Proc. 1991, 66, 1018-1028.
7. Hamazaki, T.; Tateno, S.; Shishido, H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984, 1, 1017-1018.
8. Cheng, I.K.P.; Chan, P.C.K.; Chan, M.K. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis, Nephrol, Dial. Transplant, 1990, 5, 241-246.
9. Bennett, W.M.; Walker, R.G.; Kincaid-Smith, P. Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): a two-year prospective trial. Clin. Nephrol. 1989, 31, 128-131.
10. Pettersson, E.E.; Rekola, S.; Berglund, D.; et al. Treatment of IgA nephropathy with omega-3 polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin. Nephrol. 1994, 41, 183-190.
11. Donadio, J.V., Jr; Bergstralh, E.J.; Offord, K.P.; et al. A controlled trial of fish oil in IgA nephropathy. N. Engl. J. Med. 1994, 331, 1194-1199.
12. Donadio, J.V., Jr; Grande, J.P.; Bergstralh, E.J.; et al. The long-term outcome of patients with IgA nephropathy treated with fish-oil in a controlled trial. J. Am. Soc. Nephrol. 1999, 10, 1772-1777.
13. Donadio, J.V., Jr; Larson, T.S.; Bergstralh, E.J.; et al. A randomized trial of high-dose compared to low-dose omega-3 fatty acids in severe IgA nephropathy. J. Am. Soc. Nephrol. 2001, 12, 791-799.
14. Andreoli, S.P.; Yum, N.M.; Bergstein, J.M. IgA nephropathy in children: significance of glomerular basement membrane deposition of IgA. Am. J. Nephrol. 1986, 6, 28-33.
15. Cockcroft, D.W.; Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31-41.
16. The GISEN Group (Gruppo Italiano di studi Epidemiologici in Nephrologia). Randomized, placebo-controlled trial of effects of ramipril on decline in glomerular filtration rate and risk of terminal renal failure, in proteinuric, non-diabetic nephropathy. Lancet 1997, 349, 1857-1863.
17. De Caterina, R.; Caprioli, R.; Giannessi, D.; et al. n-3 Fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int. 1993, 44, 843-850.
18. Hall, A.V.; Parbtani, A.; Clark, W.F.; et al. Omega-3 fatty acids supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J. Am. Soc. Nephrol. 1992, 3, 1321-1329.
19. Cartwright, I.J.; Pockley, A.G.; Galloway, J.H.; et al. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985, 55, 267-281.
20. Fischer, S.; Weber, P.C. Thromboxane A3 (TxA3) is formed in human platelets after dietary eicosapentaenoic acid (C20: 5ω3). Biochem. Biophys. Res. Commun. 1983. 116, 1091-1099.
21. Radford, F.M., Jr; Donadio, J.V., Jr; Bergstralh, E.J.; Grande, J.P. Predicting renal outcome in IgA nephropathy. J. Am. Soc. Nephrol. 1997, 8, 199-207.
22. Beukof, J.R.; Kardaun, O.; Schaafsma, W.; et al. Toward individual prognosis of IgA nephropathy. Clin. Invest. 1986, 29, 549-556.
23. Rekola, S.; Bergstrand, A.; Bucht, H. IgA nephropathy: a retrospective evaluation of prognostic indices in 176 patients. Scand. J. Urol. Nephrol. 1989, 23, 37-50.